Pharming Group N.V.(PHAR)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,213 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
PHAR Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Pharming Group N.V. (PHAR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PHAR at 38.0/100 on a 32-signal composite quality model, placing it at rank #2,213 of 2,961 stocks — the bottom half of the AI-ranked universe. Top institutional holders of PHAR by reported 13-F value include MAC Alpha Capital Management, Silverberg Bernstein Capital Management, Crossmark Global, based on the most recent SEC filings. PHAR trades on the Nasdaq exchange and files with the SEC under CIK 1828316. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PHAR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Pharming Group N.V. directly from SEC EDGAR. Pharming Group N.V.'s 13F Pro composite quality score has ranged between 38 and 38 since 2026, currently 38.0 — a stable long-term trajectory across 11 quarterly and live scoring snapshots.
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProTotal Assets
+25.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Total Assets | $500.0M +25.0% | $400.0M -13.6% | $462.9M +8.7% | $425.8M +7.2% | $397.3M -5.1% | $418.5M |
Get alerted when PHAR's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Pharming Group N.V. including:
Top Institutional Holders of PHAR
MAC Alpha Capital Management, LP
$2.9M2,148,144 shSilverberg Bernstein Capital Management LLC
$577.1K41,547 shCrossmark Global Holdings, Inc.
$169.0K12,463 shCITADEL ADVISORS LLC
$162.3K11,972 shMORGAN STANLEY
$159.7K11,500 shSmartHarvest Portfolios, LLC
$144.7K10,415 shKnoll Capital Management, LLC
$56.8K4,091 shSilver Grove Financial Group, Inc.
$14.9K1,071 shNalls Sherbakoff Group, LLC
$12.1K870 shGlobal Retirement Partners, LLC
$6.3K456 sh
| Fund | Value | Shares |
|---|---|---|
| MAC Alpha Capital Management, LP | $2.9M | 2,148,144 |
| Silverberg Bernstein Capital Management LLC | $577.1K | 41,547 |
| Crossmark Global Holdings, Inc. | $169.0K | 12,463 |
| CITADEL ADVISORS LLC | $162.3K | 11,972 |
| MORGAN STANLEY | $159.7K | 11,500 |
| SmartHarvest Portfolios, LLC | $144.7K | 10,415 |
| Knoll Capital Management, LLC | $56.8K | 4,091 |
| Silver Grove Financial Group, Inc. | $14.9K | 1,071 |
| Nalls Sherbakoff Group, LLC | $12.1K | 870 |
| Global Retirement Partners, LLC | $6.3K | 456 |
Companies Similar to PHAR
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Telix Pharmaceuticals Ltd
TAKEDA PHARMACEUTICAL CO LTD
P3 Health Partners Inc.
SMITH & NEPHEW PLC
Inventiva S.A.
KONINKLIJKE PHILIPS NV
AYTU BIOPHARMA, INC
ASTRAZENECA PLC
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put PHAR on your watchlist
Track score changes the day Pharming Group N.V. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is PHAR a good stock to buy?
13F Pro's AI-powered analysis of Pharming Group N.V. (PHAR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PHAR are available on the PHAR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PHAR is classified as a mid company.
Which hedge funds own PHAR?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PHAR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Pharming Group N.V.'s investment landscape.